FDA Oncology Announcements

Bcl-2 inhibitor × Clear all

6 Announcements

FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma

Trial: AMPLIFY
Drugs: Calquence (acalabrutinib) · BTK inhibitor, Venclexta (venetoclax) · Bcl-2 inhibitor
Conditions: LymphoidOther hematologic neoplasm

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia

Trial: Viale-a
Drugs: VENCLEXTA (venetoclax) · Bcl-2 inhibitor, azacitidine · DNA methyltransferase inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA approves venetoclax for CLL and SLL

Drug: VENCLEXTA (venetoclax) · Bcl-2 inhibitor
Condition: Lymphoid

FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy

Trial: MURANO
Drug: VENCLEXTA (venetoclax) · Bcl-2 inhibitor
Condition: Lymphoid

FDA approves venetoclax for CLL or SLL, with or without 17 p deletion, after one prior therapy

Drug: VENCLEXTA (venetoclax) · Bcl-2 inhibitor
Condition: Lymphoid

Venetoclax (Venclexta) Tablets

Drug: VENCLEXTA tablets (venetoclax) · Bcl-2 inhibitor